Collaboration supports co-development of RB-340 CAR T cell therapy, application of Refuge’s synthetic biology platform to MD Anderson TIL programs The University of Texas MD Anderson Cancer Center and Refuge Biotechnologies, Inc. today announced a strategic collaboration to advance new cell therapies for potential treatment of solid tumors. The agreement pairs Refuge’s innovative technologies with the experience and industrial capabilities of MD Anderson’s Biologics Development platform, within the Therapeutics Discovery division. Under the agreement, MD Anderson will possess exclusive rights to apply […]
